Cellectar Biosciences, Inc. Logo

Cellectar Biosciences, Inc.

Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.

CLRB | US

Overview

Corporate Details

ISIN(s):
US15117F8077
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, 7932 FLORHAM PARK

Description

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectar Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectar Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectar Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Emergent BioSolutions Inc. Logo
Develops and delivers medical countermeasures for public health threats and crises.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Biotechnology company developing small molecule drugs for virology and immunology.
United States of America
ENTA
Enervit Logo
Develops sports nutrition, functional foods, and wellness supplements.
Italy
ENV
enGene Holdings Inc. Logo
Clinical-stage biotech developing non-viral gene therapies for local delivery.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
Clinical-stage biopharma developing kinase inhibitors for precision oncology.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
A clinical-stage macrophage reprogramming immunotherapy company.
Israel
ENLV
Enlivex Therapeutics Ltd. Logo
Develops macrophage reprogramming immunotherapy for inflammatory diseases.
United States of America
ENLV
Enorama Pharma AB Logo
Develops and manufactures medicated chewing gums and tobacco-free nicotine pouches.
Sweden
ERMA
Ensol Biosciences Inc. Logo
AI-driven biopharma developing peptide drugs for unmet medical needs.
South Korea
140610
Entera Bio Ltd. Logo
A clinical-stage company developing oral peptide and protein replacement therapies.
United States of America
ENTX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.